Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Walter Delgaudio

Urology Plains, PA Medical Doctor

NPI 1730270968 CMS profile 305921

670 S River St Ste 301, Plains, PA 18705

Open in the dashboard

General payments

$6,497

258 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Walter Delgaudio of Plains, PA is reported in the CMS Open Payments database as having received $6,497 across 258 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $713 36
2024 General $712 36
2023 General $1,217 75
2022 General $209 11
2021 General $357 19
2020 General $590 32
2019 General $2,699 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Walter Delgaudio
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Walter Delgaudio were reported at $713. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Walter Delgaudio Urology median Middle half National median
2019 $2,699 $480 $147–$1,201 $163
2020 $590 $246 $87–$645 $114
2021 $357 $358 $111–$1,000 $132
2022 $209 $476 $143–$1,263 $149
2023 $1,217 $560 $168–$1,461 $160
2024 $712 $563 $170–$1,464 $164
2025 $713 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $2,180 17 payments
  2. Astellas Pharma US Inc $928 43 payments
  3. AbbVie, Inc. $592 34 payments
  4. Sumitomo Pharma America, Inc. $363 20 payments
  5. Myriad Genetic Laboratories, Inc. $349 10 payments
  6. Medtronic, Inc. $291 32 payments
  7. Pfizer Inc. $269 20 payments
  8. Axonics Modulation Technologies, Inc. $151 9 payments
  9. Boston Scientific Corporation $139 5 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $126 7 payments
  11. Other $1,110 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,153 252 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,000 1 payment
  3. Education $344 5 payments
Products named General payments · program years 2019–2025
  1. INTERSTIM Sacral Nerve Stimulation $2,180 17 payments
  2. XTANDI $525 37 payments
  3. MYRBETRIQ $330 21 payments
  4. GEMTESA $328 18 payments
  5. INTERSTIM Sacral Nerve Stimulation $291 32 payments
  6. PROLARIS $279 7 payments
  7. LUPRON DEPOT $261 16 payments
  8. BOTOX $235 11 payments
  9. Axonics $117 6 payments
  10. Nubeqa $108 6 payments
  11. Other $1,607 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

4,435

Median for Urology: 1,053

Drug cost

$274,524

Median for Urology: $101,464

Branded share of claims

22.6%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 252 $147,809
Gemtesa Vibegron Brand 51 $36,660
Tamsulosin Hcl Generic 1,674 $36,097
Dutasteride Generic 431 $14,266
Finasteride Generic 649 $8,698
Oxybutynin Chloride Er Oxybutynin Chloride Brand 324 $6,962
Methenamine Hippurate Generic 71 $4,884
Silodosin Generic 24 $4,283
Alfuzosin Hcl Er Alfuzosin Hcl Brand 180 $3,670
Solifenacin Succinate Generic 118 $2,561

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$141,766

Medicare's payments for the services billed

Medicare patients

789

Average age 75

Services billed

2,079

161 women, 628 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 39%
Diabetes 35%
Chronic kidney disease 29%
Cancer 28%
Atrial fibrillation 23%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $157
$157 51 —
XTANDI
  • Astellas Pharma US Inc $92
  • PFIZER INC. $5
$97 — —
BOTOX
  • AbbVie, Inc. $65
$65 — —
LUPRON DEPOT
  • AbbVie, Inc. $43
$43 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $35
  • PFIZER INC. $5
$40 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record